Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's Disease and related disorders-Reference-Cited by-同舟云学术

Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's Disease and related disorders

Published:2000-12 Issue:3 Volume:88 Page:427-435
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Rouse Susan T,Marino Michael J,Bradley Stefania R,Awad Hazar,Wittmann Marion,Conn P.Jeffrey

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference68 articles.

1. The functional anatomy of basal ganglia disorders;Albin;Trends Neurosci,1989

2. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity–akinesia;Albin;Ann Neurol,1990

3. Parallel organization of functionally segregated circuits linking basal ganglia and cortex;Alexander;Annu Rev Neurosci,1986

4. Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization;Anderson;J Comp Neurol,1990

5. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity;Anwyl;Brain Res Brain Res Rev,1999

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The antisaccadic paradigm: A complementary neuropsychological tool in basal ganglia disorders;Cortex;2024-09

2. Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease;Cells;2023-03-24

3. Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence;Current Neuropharmacology;2023-03

4. Modulation of Hippocampal Network Oscillation by PICK1-Dependent Cell Surface Expression of mGlu3 Receptors;The Journal of Neuroscience;2022-10-06

5. Glutamatergic Treatments for Parkinson’s Disease;Glutamate and Neuropsychiatric Disorders;2022